Fort Wayne, INNCT07756645Now EnrollingIRB Ready

Non-Small Cell Lung Cancer Clinical Trial in Fort Wayne, IN

Access cutting-edge non-small cell lung cancer treatment through this phase 3 clinical trial at a research site in Fort Wayne. Study-provided care at no cost to qualified participants.

Sponsored by AbbVie

Quick Self-Assessment

See if you qualify for this Fort Wayne location

Preparing your pre-screening questions…

Expert Care in Fort Wayne

Access non-small cell lung cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related non-small cell lung cancer treatment provided free

Apply for This Fort Wayne Location

Check if you qualify for this non-small cell lung cancer clinical trial in Fort Wayne, IN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Fort Wayne

    Convenient for IN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Fort Wayne site if eligible
  4. 4Begin participation

About This Non-Small Cell Lung Cancer Study in Fort Wayne

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases. Squamous carcinoma accounts for 20-30% of all NSCLC cases. The purpose of this study is to determine if ABBV-1480 plus chemotherapy works better than pembrolizumab plus chemotherapy in adult participants with NSCLC. ABBV-1480 is an investigational drug being developed for the treatment of NSCLC. Participants will be randomized into 2 groups. One group will receive ABBV-1480 with platinum based chemotherapy. Another group will receive standard of care (SOC) pembrolizumab with platinum based chemotherapy. Up to approximately 940 adult participants with locally advanced (Stage IIIB/C) or metastatic (Stage IV) sqNSCLC, will be enrolled in the study in approximately 250 sites globally. In this Phase 3 study one of two groups will receive doses of Intravenous (IV) ABBV-1480 + Carboplatin \& Paclitaxel/ Nab-paclitaxel and other group will receive Intravenous (IV) Pembrolizumab + Carboplatin \& Paclitaxel/ Nab-paclitaxel. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Sponsor: AbbVie

Who Can Participate

Inclusion Criteria

Adult subjects with a histologically or cytologically confirmed diagnosis of Stage IIIB, IIIC, or IV sqNSCLC that is not amenable to curative treatment
At least one lesion with measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by the local site investigator/radiology assessment.
Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Adequate hematological, renal, hepatic, and coagulation function.
Females of childbearing potential must have a negative pregnancy test

Exclusion Criteria

Prior systemic treatment received for locally advanced or metastatic NSCLC.
Histologically or cytologically confirmed non-sqNSCLC.
Known actionable genomic alterations (including EGFR, ALK, ROS1, BRAF, NTRK, RET, and MET) for which first-line approved therapies are available.
Active central nervous system (CNS) metastases and/or carcinomatous meningitis.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Fort Wayne?

Yes, this clinical trial (NCT07756645) has an active research site in Fort Wayne, IN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-Small Cell Lung Cancer Treatment Options in Fort Wayne, IN

If you're searching for non-small cell lung cancer treatment options in Fort Wayne, IN, this clinical trial (NCT07756645) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Fort Wayne research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced non-small cell lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-small cell lung cancer clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Fort Wayne, IN

See all lung cancer clinical trials recruiting in Fort Wayne — not just this study.

Browse Lung Cancer Trials in Fort Wayne →

Ready to Join in Fort Wayne?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Fort Wayne, IN